ihbt12b2513109.htm
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE
FILING
|
SEC
File Number: 333-57946
|
|
CUSIP
Number: 45719U 10
0
|
(Check One):xForm 10-K
¨ Form
20-F ¨ Form 11-K
¨Form 10-Q ¨ Form
N-SAR
For
Period Ended: January 31,
2009
¨
Transition Report on Form 10-KSB
¨
Transition Report on Form 20-F
¨
Transition Report on Form 11-K
¨
Transition Report on Form 10-QSB
¨
Transition Report on Form N-SAR
For the
Transition Period Ended: ___________________
Read Instruction (on back
page) Before Preparing Form. Please Print or Type.
|
Nothing in this form shall be
construed to imply that the Commission has verified any information
contained herin.
|
If the notification relates
to a portion of the filing checked above, identify the Item(s) to which the
notification relates:
PART
I -- REGISTRANT INFORMATION
|
Inhibiton Therapeutics,
Inc.
Full
Name of Registrant
|
_________________________
Former
Name if Applicable
|
7315 E. Peakview
Avenue
Address
of Principal Executive Office (Street and
Number)
|
Englewood, Colorado
80111
City,
State and Zip Code
|
PART II -- RULES 12b-25(b) AND
(c)
If the
subject report could not be filed without unreasonable effort or expense and the
registrant seeks relief pursuant to Rule 12b-25(b), the following should be
completed. (Check box if appropriate)
x
|
(a)
The reasons described in reasonable detail in Part III of this form could
not be eliminated without unreasonable effort or expense;
(b)
The subject annual report, semi-annual report, transition report on Form
10-KSB , Form 20-F,11-K or Form N-SAR, or portion thereof, will be filed
on or before the fifteenth calendar day following the prescribed due date;
or the subject quarterly report or transition report on Form 10-QSB, or
portion thereof will be filed on or before the fifth calendar day
following the prescribed due date; and
(c)
The accountant's statement or other exhibit required by Rule 12b-25(c) has
been attached if applicable.
|
PART III -- NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR,
or the transition report portion thereof, could not be filed within the
prescribed time period.
Inhibiton Therapeutics, Inc., a
Nevada Corporation, hereby requests an extension until May 18, 2009,
for the filing of its Annual Report on Form 10-K for the year ended January
31, 2009. This additional time is necessary for the Registrant to complete
preparation of the required financial statements. The Registrant plans to file
the Form 10-K as soon as reasonably practicable.
PART IV-- OTHER
INFORMATION
(1) Name
and telephone number of person to contact in regard to this notification
|
Thomas B.
Olson
(Name)
|
(303)
(Area
Code)
|
796-8940
(Telephone
Number)
|
(2) Have
all other periodic reports required under Section 13 or 15(d) of the Securities
Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during
the preceding 12 months or for such shorter period that the registrant was
required to file such report(s) been filed? If answer is no, identify report(s).
xYes
¨No
(3) Is it
anticipated that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by the earnings
statements to be included in the subject report or portion thereof? ¨Yes
xNo
If so,
attach an explanation of the anticipated change, both narratively and
quantitatively, and, if appropriate, state the reasons why a reasonable estimate
of the results cannot be made.
Inhibiton Therapeutics,
Inc.
(Name of
Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: May 4,
2009
|
By:/s/ Thomas B.
Olson
Thomas
B. Olson, Secretary
|
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other
duly authorized representative. The name and title of the person signing the
form shall be typed or printed beneath the signature. If the statement is signed
on behalf of the registrant by an authorized representative (other than an
executive officer), evidence of the representative's authority to sign on behalf
of the registrant shall be filed with the form.
ATTENTION
Intentional misstatements or
omissions of fact constitute Federal Criminal Violations (See 18 U.S.C.
1001).
|
General
Instructions
1. This
form is required by Rule 12b-25 (17 CFR 240.12b-25) of the General Rules and
Regulations under the Securities Exchange Act of 1934.
2. One
signed original and four conformed copies of this form and amendments thereto
must be completed and filed with the Securities and Exchange Commission,
Washington, D.C. 20549, in accordance with Rule 0-3 of the General Rules and
Regulations under the Act. The information contained in or filed with the form
will be made a matter of public record in the Commission files.
3. A
manually signed copy of the form and amendments thereto shall be filed with each
national securities exchange on which any class of securities of the registrant
is registered.
4.
Amendments to the notifications must also be filed on Form 12b-25 but need not
restate information that has been correctly furnished. The form shall be clearly
identified as an amended notification.
5.
Electronic filers. This
form shall not be used by electronic filers unable to timely file a report
solely due to electronic difficulties. Filers unable to submit a report within
the time period prescribed due to difficulties in electronic filing should
comply with either Rule 201 or
Rule 202 of
Regulation S-T (§232.201 or §232.202 of this chapter) or apply for an adjustment
in filing date pursuant to Rule 13(b) of Regulation S-T (§232.13(b) of this
Chapter).